Improved glioblastoma treatment through targeted, local drug delivery (TARGLIO)

Purpose and goal:

DBP has been able to strengthen the application for the EIC accelerator in 2021 and a resubmission for EIC accelerator will be done. Actions taken are an economic market analysis and consultation with PlantVision AB regarding the regulatory part, a clinical drug quality system protocol and update. The meetings in Germany and the Netherlands with the clinical principal investigators were crucial in discussing current and future aspects of the clinical trials. We will submit a new EIC accelerator application in 2023/2024 for Phase 2 clinical trials.

Expected results and effects:

Due to the grant, we have carried out the work packages that were specified. The financial history and update company valuations and future forecasts were established. We have received support in regulatory affairs.

The visits to Germany and the Netherlands have been extremely valuable in strengthening the collaboration and being able to communicate more smoothly with all the partners involved. Overall, this project has strengthened our business model and allowed us to obtain permission to conduct Phase 1 clinical trials from regulatory authorities in German and the Nederland.

Approach and implementation:

The structure and objectives of the work packages were at a good level, which meant that the majority of the steps could be carried out according to the time frame. However, there were some logistical challenges thanks to restrictions from the Covid 19 pandemic, which meant that the planned meetings at the clinical sites had to be rescheduled to a later date.